PEPTIDE COMPARISON

Epitalon vs SS-31

A longevity research peptide compared with a molecule that has one rare-disease accelerated approval.

QUICK ANSWER

Epitalon vs SS-31: the main difference.

SS-31, as elamipretide, has crossed a regulatory threshold that Epitalon has not. The approval is limited to a rare-disease indication and does not support general longevity use.

Decision field	Epitalon	SS-31 / Elamipretide
Human research	Very limited and uncertain	Small rare-disease clinical program
Primary research	Aging and oxidative models	Mitochondrial cardiolipin and Barth syndrome
FDA status	Not approved	Accelerated approval for one narrow indication
Main overreach	Anti-aging claims from weak evidence	Generalizing rare-disease approval to longevity
Evidence confidence	Very low	Moderate only for the labeled use

SOURCES

Epitalon vs SS-31 sources.

Review / 2025Epitalon: structural, physicochemical, and biological research reviewPubMed Government / 2023Compounding pharmacy plea involving unlawful unapproved drug distributionU.S. Department of Justice WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2025FDA grants accelerated approval to first treatment for Barth syndromeU.S. FDA FDA / 2025Forzinity prescribing informationU.S. FDA

Epitalon vs SS-31: the main difference.

Epitalon vs SS-31 sources.

Questions related to Epitalon vs SS-31.

Compare the next decision.